Mesangiolysis occurs in many renal diseases, both human and experimental. At least three types of mesangiolysis may be recognized, which differ in their mode of origin and in morphologic features. The first type is severe mesangiolysis with formation of glomerular cysts and subsequent cellular proliferation resembling glomerulonephritis. In the second type, mesangiolysis is associated with extensive widening of the subendothelial space and is thought to follow endothelial injury. The third type is mesangiolysis with lamellated mesangial nodules which is believed to result from relatively mild but persistent or recurrent localized mesangial, and perhaps also endothelial damage, with lysis of mesangial anchor points.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1053/ajkd.1998.v31.pm9531171 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Kidney lesions and risk of cardiovascular events in biopsy-proven diabetic kidney disease with type 2 diabetes.
Clin Exp Nephrol
October 2024
Department of Nephrology and Rheumatology, Graduate School of Medical Sciences, Kanazawa University, 13-1 Takara-machi, Kanazawa, 920-8640, Japan.
Background: This study assessed the association of pathological kidney lesions with cardiovascular events in biopsy-proven diabetic kidney disease (DKD) with type 2 diabetes.
Methods: This multicenter, retrospective study involved 244 patients with no previous cardiovascular events before biopsy, estimated glomerular filtration rate (eGFR) ≥ 30 mL/min/1.73 m at biopsy (baseline), and ≥ 1 year of observation after biopsy.
Mesangiolysis in Pathological Chronic Active Antibody-Mediated Rejection in Kidney Transplant Biopsies.
Nephron
November 2023
Department of Nephrology, Toho University Faculty of Medicine, Tokyo, Japan.
Introduction: This study aimed to determine if immune or nonimmune and acute or chronic lesions associated with mesangiolysis (MGLS) occurred in biopsy-proven pathological chronic active antibody-mediated rejection (P-CAABMR) in kidney transplant biopsies.
Methods: We evaluated MGLS in 41 patients with biopsy findings of P-CAABMR from January 2016 to December 2019. Histological scoring was evaluated by Banff classification.
Crescents, an Independent Risk Factor for the Progression of Type 2 Diabetic Kidney Disease.
J Clin Endocrinol Metab
September 2022
Department of Nephrology, the Second Xiangya Hospital of Central South University, Changsha, Hunan, China.
Context: Crescents have been noticed in pathologic changes in patients with diabetic kidney disease (DKD). However, the clinical significance of crescents is still not well recognized.
Objective: The main objective was to investigate the association between crescents and the prognoses of type 2 DKD (T2DKD) patients, and, secondly, to analyze the relationship between crescents and clinicopathologic features.
We encountered a 77-year-old Japanese man who presented with nephrotic-range proteinuria 20 days after receiving ramucirumab treatment for metastatic sigmoid colon cancer. A kidney biopsy showed two characteristic histological findings. The first finding was podocyte injury with cellular crescent-like formation, although focal segmental glomerulosclerosis (FSGS) (collapsing variant) according to the Columbia classification may have been a more appropriate name for this injury, as hypertrophy and hyperplasia of epithelial cells, presumably resulting from podocyte injury, were seen between Bowman's capsule and the glomerular basement membrane (GBM); these changes appeared to be due to the collapse of the GBM rather than to GBM destruction with fibrinoid necrosis.
View Article and Find Full Text PDFChild Neurology: Pathologically Confirmed Thrombotic Microangiopathy Caused by Onasemnogene Abeparvovec Treatment for SMA.
Neurology
May 2022
From the Department of Pediatrics (K.Y., S.S., N.H., T.H.), Osaka Metropolitan University Graduate School of Medicine; and Department of Pediatrics (R.F.), Osaka City General Hospital, Japan.
Onasemnogene abeparvovec is an adeno-associated virus vector-based gene therapy for spinal muscular atrophy (SMA). Although several cases of drug-induced thrombotic microangiopathy due to onasemnogene abeparvovec have been reported, none has been confirmed pathologically. Here, we present renal histopathologic findings of TMA due to onasemnogene abeparvovec.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!